Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.87 USD | +2.80% | +3.44% | -40.27% |
May. 29 | Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating | MT |
May. 28 | Cytokinetics Closes $500 Million Stock Offering | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.27% | 5.57B | B | ||
+15.55% | 118B | B+ | ||
+12.66% | 106B | B+ | ||
-2.53% | 24.28B | B+ | ||
+1.14% | 21.96B | B | ||
-9.35% | 18.16B | A- | ||
-42.28% | 16.37B | A- | ||
-18.92% | 15.56B | B | ||
+6.19% | 13.63B | C+ | ||
+28.83% | 12.27B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CYTK Stock
- Ratings Cytokinetics, Incorporated